Goldman Sachs
IMDX

Goldman Sachs’s Insight Molecular Diagnostics IMDX Stock Holding History

Goldman Sachs’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-23,965
Closed -$180K – 6845
2025
Q4 		$180K Buy
+23,965
New +$135K ﹤0.01% 6063
2023
Q1 		– Sell
-3,077
Closed -$19.8K – 6138
2022
Q4 		$19.8K Sell
3,077
-16,000
-84% -$176K ﹤0.01% 5700
2022
Q3 		$279K Sell
19,077
-8,022
-30% -$139K ﹤0.01% 5333
2022
Q2 		$487K Buy
27,099
+4,099
+18% +$93.2K ﹤0.01% 5098
2022
Q1 		$686K Buy
23,000
+1,248
+6% +$39.9K ﹤0.01% 5121
2021
Q4 		$944K Buy
21,752
+876
+4% +$50.4K ﹤0.01% 4899
2021
Q3 		$1.49M Buy
20,876
+1,683
+9% +$155K ﹤0.01% 4441
2021
Q2 		$2.2M Buy
19,193
+10,754
+127% +$1.05M ﹤0.01% 4113
2021
Q1 		$876K Buy
8,439
+700
+9% +$66.5K ﹤0.01% 4714
2020
Q4 		$370K Sell
7,739
-932
-11% -$34.2K ﹤0.01% 4783
2020
Q3 		$241K Buy
8,671
+7,103
+453% +$204K ﹤0.01% 4841
2020
Q2 		$60K Buy
1,568
+608
+63% +$31.4K ﹤0.01% 5052
2020
Q1 		$47K Buy
+960
New +$47.1K ﹤0.01% 5061
2018
Q3 		– Sell
-923
Closed -$47K – 5734
2018
Q2 		$47K Sell
923
-538
-37% -$26.5K ﹤0.01% 5365
2018
Q1 		$61K Buy
+1,461
New +$96.5K ﹤0.01% 5418
2017
Q3 		– Sell
-2,101
Closed -$218K – 6790
2017
Q2 		$218K Buy
2,101
+263
+14% +$29.9K ﹤0.01% 5742
2017
Q1 		$219K Buy
+1,838
New +$212K ﹤0.01% 5672
2016
Q3 		– Sell
-1,478
Closed -$105K – 7130
2016
Q2 		$105K Buy
1,478
+20
+1% +$1.87K ﹤0.01% 6105
2016
Q1 		$134K Buy
+1,458
New +$129K ﹤0.01% 5907

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Goldman Sachs's IMDX Position: Q1 2026 in Review

Goldman Sachs sold out of Insight Molecular Diagnostics (IMDX) in Q1 2026, closing a stake of 23,965 shares — an estimated $180K sold.

Goldman Sachs first reported a position in IMDX in Q1 2016 and held it in 19 quarters. The position peaked at $2.2M in Q2 2021. 41 funds tracked by Wall St. Rank hold IMDX as of Q1 2026.

  • Goldman Sachs reported no remaining Insight Molecular Diagnostics position as of Q1 2026 after selling out during the quarter.
  • Goldman Sachs sold 23,965 Insight Molecular Diagnostics shares in Q1 2026, an estimated $180K.
  • Goldman Sachs first reported a position in Insight Molecular Diagnostics in Q1 2016 and held it in 19 quarters.
  • Goldman Sachs's Insight Molecular Diagnostics position peaked at $2.2M in Q2 2021.
  • 41 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.